Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fortress Adds New Rare Disease-Focused Subsidiary

Executive Summary

Cyprium joins Fortress’ growing company portfolio, which now includes nine subsidiaries focused on a broad range of disease. Fortress CEO Rosenwald aims to add one to two new companies a quarter under the Fortress umbrella.

You may also be interested in...



Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug

Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.

IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First

Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.

Fortress Biotech: A Drug Financing Experiment Expands

Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel